Posted by Michael Wonder on 04 Mar 2026
Boryung adds Xpovio to blood cancer portfolio under Antengene license deal
4 March 2026 - Boryung said Wednesday that it has signed a license in deal with Antengene, a Chinese pharmaceutical company specializing in the development of anticancer drugs, for the blood cancer drug Xpovio (selinexor).
Under this agreement, Boryung secured exclusive rights to Xpovio in Korea, including domestic sales, distribution, and licensing, and began full scale domestic distribution last month.
